Clinipace expands its CRO offering with new acquisition

Clinipace Worldwide has announced the acquisition of Paragon Biomedical.

Clinipace Worldwide has announced the acquisition of Paragon Biomedical, a global full-service contract research organistation (CRO).

The company, which specialises in digital CRO services, is using the latest addition to its portfolio of businesses to improve its therapeutic expertise, as well as boosting its site management capabilities and clinical operations handling.

As a result of the deal, it will now also possess new offices in Irvine, California, High Wycombe, India and the UK.

Jeff Williams, chief executive of Clinipace, said: "Paragon is an ideal partner to achieve our common long-term goals to drive innovation in clinical research through a technology-amplified service platform."

He added that merging the two companies will create a foundation for a "more compelling service", as well as a differentiated and high-tech platform for clinical operations.

In particular, the acquisition allows Clinipace Worldwide to improve the strength of its oncology franchise, will also expanding into areas of therapeutic expertise relating to cardiovascular, immunology, infectious diseases, central nervous system, respiratory and dermatology services.